The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable buzz within the market. A shift away from Schedule I status, often considered as outdated and hindering innovation, could unlock significant possibilities for ventures. Reduced regulatory restrictions, alongside greater access to banking and ca